All In MedTech

Device Trial Radar · NCT07281599

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Dec 31, 2026

Study completion Mar 2027

Sponsor

Lead sponsor
QurasenseNot on our public-company list
Sponsor type
Industry
First posted
Dec 15, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Female only, from 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.

Conditions

  • HPV Infection
  • HPV 16 Infection
  • High Risk HPV
  • Cervical Cancer Screening
  • Cervical Cancer Cin Grade
  • Cervical Cancer (Early Detection)
  • HPV
  • HPV (Human Papillomavirus)-Associated
  • HPV DNA
  • HPV Infections
  • Screening Test

Interventions

  • Q-Pad hrHPV Test SystemDevice

    Participants will receive a mailed Q-Pad Kit, which includes two Q-Pads (menstrual pads with removable collection strips called Q-Strips), a Q-Strip Container with desiccant for storing and shipping the strips, and a prepaid return mailer. During the menstrual cycle after their colposcopy visit, participants will follow the Instructions for Use to passively collect menstrual blood with the Q-Pads, then remove the Q-Strips and place them in the Q-Strip Container for mailing to the central laboratory for hrHPV testing. At the colposcopy visit, the clinician will also collect a cervical sample in ThinPrep liquid-based cytology medium for hrHPV testing, which will serve as the comparator specimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Performance vs HistologyTime frame: Through study completion, an average of 1 year.
  2. Proportion of participants with at least one reportable device-related adverse event (ADE or SADE)Time frame: Through study completion, an average of 1 year.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Planned Parenthood of Southern New England

    New Haven, Connecticut · Recruiting

  • Planned Parenthood North Central States

    Minneapolis, Minnesota · Recruiting

  • Planned Parenthood of Greater Ohio (PPGOH)

    Akron, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.